Cellebrite DI Ltd

Análisis de la acción Cellebrite DI Ltd (CLBT)

$11.030

-0.340 (-3.08%)Al cierre

Loading chart…
Máximo
11.480
Apertura
11.450
Precio medio ponderado por volumen
11.12
Volumen
1.53M
Capitalización
2.43B
Mínimo
10.850
Importe
17.04M
EV/EBITDA, TTM
48.51

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.

www.cellebrite.com

Análisis de IA of Cellebrite DI Ltd (CLBT)

Mantener

Cellebrite DI Ltd is not a strong buy right now due to its current price of $11.03, which is significantly below the average analyst price target of $20. However, the stock has shown a 21% year-over-year growth in annual recurring revenue, indicating potential for recovery. The main risk is the recent earnings miss with an EPS surprise of -44.44%, suggesting that the company's financial performance may not meet investor expectations in the near term.

Métricas de valoración

El PER previsto actual de Cellebrite DI Ltd (CLBT) es 35.71, frente a su media de 5 años de 41.27.

PER previsto

Valor razonable
Media 5A P/E
41.27
P/E actual
35.71
Sobrevalorada
57.56
Infravalorada
24.98

EV/EBITDA previsto

Sobrevalorado
Media 5A EV/EBITDA
30.09
EV/EBITDA actual
48.51
Sobrevalorada
42.38
Infravalorada
17.80

Precio/ventas previsto

Valor razonable
Media 5A P/S
5.65
P/S actual
4.46
Sobrevalorada
7.91
Infravalorada
3.39

Escenarios de precio de Alphio AI para CLBT

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%CLBT

$24.00

Precio del escenario

B

Base

Base · 50%CLBT

$20.91

Precio del escenario

B

Bajista

Bajista · 25%CLBT

$20.21

Precio del escenario

Ballenas con CLBT en cartera

P

Phoenix Investments & Finances Ltd

+ Con en carteraCLBT

+8.81%

Rentabilidad a 3 meses

C

Clal Financial Management Ltd

+ Con en carteraCLBT

-2.97%

Rentabilidad a 3 meses

W

Weiss Asset Management, LLC

+ Con en carteraCLBT

-4.94%

Rentabilidad a 3 meses

V

Voss Capital, LP

+ Con en carteraCLBT

-5.54%

Rentabilidad a 3 meses

P

Portolan Capital Management, LLC

+ Con en carteraCLBT

-7.36%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-14 (ET)

08:30:00

Cellebrite Board Approves Corporate Reorganization Plan

2026-09-02 (ET)

09:00:00

Cellebrite Guardian Achieves IRAP Certification

2026-08-13 (ET)

16:30:00

Major Averages Rise as Oil Prices Fall

12:30:00

Cellebrite Shares Drop 31.8% to $10.40

12:00:00

Major Averages Rise as Oil Prices Fall

Noticias

Preguntas frecuentes sobre CLBT, respondidas por Alphio AI

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. It operates in the Technology sector.

Cellebrite DI Ltd is not a strong buy right now due to its current price of $11.03, which is significantly below the average analyst price target of $20. However, the stock has shown a 21% year-over-year growth in annual recurring revenue, indicating potential for recovery. The main risk is the recent earnings miss with an EPS surprise of -44.44%, suggesting that the company's financial performance may not meet investor expectations in the near term.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar